Analysis of Gut Microbiota and Their Metabolic Potential in Patients with Schizophrenia Treated with Olanzapine: Results from a Six-Week Observational Prospective Cohort Study
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Accumulating evidence indicates the potential effect of microbiota on the pathogenesis and course of schizophrenia. However, the effects of olanzapine, second-generation antipsychotics, on gut microbiota have not been investigated in humans. This study aimed to analyze fecal microbiota in schizophrenia patients treated with olanzapine during six weeks of their hospital stay. After a seven-day washout from all psychotropic medications, microbiota compositions were evaluated at baseline and after six weeks of hospitalization using 16S rRNA sequencing. The study was conducted in 20 inpatients, who followed the same hospital routine and received 5–20 mg daily doses of olanzapine. Olanzapine treatment was associated with clinical improvements in all patients and significant increases in body mass index in females, but not changes in gut microbiota compositions and predicted function. The severity of symptoms at the beginning of treatment varied in accordance with the predicted metabolic activity of the bacteria. The present findings indicate that the microbiota of schizophrenia patients is highly individual and has different taxonomical (Type 1, with a predominance of Prevotella, and Type 2 with a higher abundance of Bacteroides, Blautia and Clostridium) and functional clusters, and it does not change following six weeks of olanzapine therapy; in addition, the microbiota is not associated with either the weight gain observed in women or the effectiveness of olanzapine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the gut microbiota composition did not change after 6 weeks of treatment with olanzapine in patients with schizophrenia [191].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322 · cited 1×
“2)) [41] and ComplexHeatmap [42], and custom-made scripts.”
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 2×
“The predicted metagenomes were analyzed with HUMAnN [39] and LEfSe [40].”
MethodVSEARCH: a versatile open source tool for metagenomics
(2016) · doi:10.7717/peerj.2584 · Cited by 10,773
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034 · cited 2×
“2)) [41] and ComplexHeatmap [42], and custom-made scripts.”
InfluentialPredictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548 · cited 1×
“[43]), and that for cluster type 2A to enterotype 1 (Figure 2d in Arumugam et al.”
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“It was shown that microbiome composition changed detectably within 24 h of initiating a high-fat/low-fiber or low-fat/high-fiber diet, but that enterotype identity remained stable during the 10-day study [73].”
BackgroundRecognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251 · cited 1×
“Although mechanisms underlying the potential effect of microbiota on the pathogenesis and course of SZ are yet to be determined, chronic inflammation [12] and altered tryptophan metabolism [13,14] have been suggested to be implicated in the pathogenesis of SZ.”
BackgroundSudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X., Kubo, C., & Koga, Y. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.063388 · Cited by 2,735
Cited by
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota?
Misiak, B., Łoniewski, I., Marlicz, W., Frydecka, D., Szulc, A., Rudzki, L., & Samochowiec, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109951 · Cited by 343
Self-citationMicrobiota medicine: towards clinical revolution
Gebrayel, P., Nicco, C., Al Khodor, S., Bilinski, J., Caselli, E., Comelli, E. M., Egert, M., Giaroni, C., Karpinski, T. M., Loniewski, I., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03296-9 · Cited by 276
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
Altered gut microbiota associated with symptom severity in schizophrenia
Li, S., Zhuo, M., Huang, X., Huang, Y., Zhou, J., Xiong, D., Li, J., Liu, Y., Pan, Z., Li, H., et al. (2020) · PeerJ · doi:10.7717/peerj.9574 · Cited by 142
Spichak, S., Bastiaanssen, T. F. S., Berding, K., Vlckova, K., Clarke, G., Dinan, T. G., & Cryan, J. F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.044 · Cited by 127
The Role of Cytokines in the Pathogenesis of Schizophrenia
Dawidowski, B., Górniak, A., Podwalski, P., Lebiecka, Z., Misiak, B., & Samochowiec, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173849 · Cited by 102
“Moreover, an altered composition of gut microbiota persists despite treatment with olanzapine, which does not appear to have a significant effect on it [94].”
BackgroundSelf-citationThe Microbiota–Gut–Brain Axis and Neurological Disorders: A Comprehensive Review
Nakhal, M. M., Yassin, L. K., Alyaqoubi, R., Saeed, S., Alderei, A., Alhammadi, A., Alshehhi, M., Almehairbi, A., Houqani, S. A., BaniYas, S., et al. (2024) · Life · doi:10.3390/life14101234 · Cited by 154
Mind, Mood and Microbiota—Gut–Brain Axis in Psychiatric Disorders
Toader, C., Dobrin, N., Costea, D., Glavan, L.-A., Covache-Busuioc, R.-A., Dumitrascu, D.-I., Bratu, B.-G., Costin, H. P., & Ciurea, A. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063340 · Cited by 103
“However, a study involving adult schizophrenia patients treated with olanzapine did not find analogous results in human fecal microbiota, suggesting a more complex interaction in humans [137].”
ResultOlanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis
Zhu, Z., Gu, Y., Zeng, C., Yang, M., Yu, H., Chen, H., Zhang, B., & Cai, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.897926 · Cited by 100
“Recently, the changes in gut microbiota in patients with schizophrenia taking OLZ have been studied (Pelka-Wysiecka et al., 2019).”
BackgroundYuan, X., Wang, Y., Li, X., Jiang, J., Kang, Y., Pang, L., Zhang, P., Li, A., Lv, L., Andreassen, O. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01531-3 · Cited by 73
The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment
Liu, J. C. W., Gorbovskaya, I., Hahn, M., & Müller, D. J. (2021) · Nutrients · doi:10.3390/nu13041152 · Cited by 74
“No significant changes were observed in alpha diversity and GMB composition [39].”
BackgroundPsycho-Pharmacomicrobiomics: A Systematic Review and Meta-Analysis
Minichino, A., Preston, T., Fanshawe, J. B., Fusar‐Poli, P., McGuire, P. K., Burnet, P. W. J., & Lennox, B. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.019 · Cited by 65
“Baseline In patients that gained weight (≥5 kg) = alpha diversity = beta diversity ↑ Parabacteroidetes, Eubacterium halii Jo urn al Pr e-p roo f 22 After treatment In patients that gained weight (≥5 kg) = alpha diversity = beta diversity ↓ Parabacteroidetes In patients that did not gain weight ( 5 kg): = alpha diversi…”
BackgroundInfluentialGut Biofactory—Neurocompetent Metabolites within the Gastrointestinal Tract. A Scoping Review
Skonieczna‐Żydecka, K., Jakubczyk, K., Maciejewska, D., Janda, K., Kaźmierczak-Siedlecka, K., Kaczmarczyk, M., Łoniewski, I., & Marlicz, W. M. (2020) · Nutrients · doi:10.3390/nu12113369 · Cited by 54
“In such patients treated with ol nzapine, clustering the study cohort according to Prevotella genus consequently predicted differentially abundant pathways, including carbohydrate metabolism, by means of linear discriminant analysis with effect size [59].”
MethodThe gut microbiome and antipsychotic treatment response
Seeman, M. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112886 · Cited by 47
Ling, Z., Jin, G., Yan, X., Cheng, Y., Shao, L., Song, Q., Liu, X., & Zhao, N. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.886872 · Cited by 49
“Recently, the role of non-human genetic factors such as gut microbiota has been identified in the pathophysiology of SZ (Nguyen et al., 2019; Pełka-Wysiecka et al., 2019; Li et al., 2020; Ma et al., 2020b; Pan et al., 2020; Zhu et al., 2020a; Zhu et al., 2020b; Li et al., 2021a; Yuan et al., 2021; Fan et al., 2022; Mu…”
BackgroundGut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
Singh, R., Stogios, N., Smith, E., Lee, J., Maksyutynska, K., Au, E., Wright, D. C., Palma, G. D., Graff‐Guerrero, A., Gerretsen, P., et al. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221096525 · Cited by 44
Mosquera, F. E. C., Guevara-Montoya, M. C., Serna-Ramirez, V., & Liscano, Y. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040391 · Cited by 59
Inflammation in Mental Disorders: Is the Microbiota the Missing Link?
Marin, S., Hé, Y., Butler, K., & Tsuang, M. T. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00535-1 · Cited by 49
The impact of common pharmaceutical excipients on the gut microbiota
Subramaniam, S., Kamath, S., Ariaee, A., Prestidge, C. A., & Joyce, P. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2223937 · Cited by 43
Gut microbiota and microbiome in schizophrenia
Samochowiec, J., & Misiak, B. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000733 · Cited by 48
“biota after a 6-week monotherapy with olanzapine in patients with schizophrenia [24].”
BackgroundLi, Z., Qing, Y., Cui, G., Li, M., Liu, T., Zeng, Y., Zhou, C., Hu, X., Jiang, J., Wang, D., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.005 · Cited by 37
Ling, Z., Cheng, Y., Liu, X., Yan, X., Wu, L., Shao, L., Gao, J., Lei, W., Song, Q., Zhao, N., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02682-1 · Cited by 36
Misera, A., Łoniewski, I., Palma, J., Kulaszyńska, M., Czarnecka, W., Kaczmarczyk, M., Liśkiewicz, P., Samochowiec, J., & Skonieczna‐Żydecka, K. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1125022 · Cited by 30
“The severity of symptoms at the beginning of therapy varied depending on the expected metabolic activity of the microbiota (Pełka-Wysiecka et al., 2019).”
BackgroundEffects of antipsychotics on the gastrointestinal microbiota: A systematic review
Dias, M. F., Nogueira, Y. J. D. A., Romano‐Silva, M. A., & de Miranda, D. M. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115914 · Cited by 30
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
Munawar, N., Ahmad, A., Anwar, M. A., & Muhammad, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052625 · Cited by 32
Gokulakrishnan, K., Nikhil, J., Viswanath, B., Thirumoorthy, C., Narasimhan, S., Devarajan, B., Joseph, E., David, A. K. D., Sharma, S., Vasudevan, K., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.021 · Cited by 29
The schizophrenia and gut microbiota: A bibliometric and visual analysis
Yang, C., Lin, X., Wang, X., Liu, H., Huang, J., & Wang, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1022472 · Cited by 30
Gong, X., Liu, Y., Liu, X., Li, A. Q., Guo, K., Zhou, D., & Hong, Z. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105340 · Cited by 25
Schoretsanitis, G., Dubath, C., Grosu, C., Piras, M., Laaboub, N., Ranjbar, S., Ansermot, N., Crettol, S., Vandenberghe, F., Gamma, F., et al. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13715 · Cited by 30
Zheng, J., Lin, Z., Ko, C., Xu, J., Lin, Y., & Wang, J. (2022) · Behavioural Neurology · doi:10.1155/2022/4262094 · Cited by 23
“A recent study found that olanzapine therapy in patients with SCZ altered gut microbiota including their metabolism [12].”
BackgroundThe Microbiota/Microbiome and the Gut–Brain Axis: How Much Do They Matter in Psychiatry?
Marazziti, D., Buccianelli, B., Palermo, S., Parra, E., Arone, A., Beatino, M. F., Massa, L., Carpita, B., Barberi, F. M., Mucci, F., et al. (2021) · Life · doi:10.3390/life11080760 · Cited by 26
“However, evidence on this matter is still controversial, as different studies did not detect similar effects of APs in the modulation of gut microbiota [165,166].”
ResultChen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
Misera, A., Kaczmarczyk, M., Łoniewski, I., Liśkiewicz, P., Podsiadło, K., Misiak, B., Skonieczna‐Żydecka, K., & Samochowiec, J. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107208 · Cited by 19
“Cohorts of SCZ and MDD sufferers have been described in previous studies that assessed the effects of psychotropic drugs on the micro-biome (Li ´ skiewicz et al., 2021, 2019; Pe ł ka-Wysiecka et al., 2019).”
BackgroundMethodFang, X., Gao, C., Wu, W., Hu, X., Shao, M., Zhou, C., Cai, R., Fang, J., Li, Y., Xu, Y., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115463 · Cited by 12
Early prediction of olanzapine-induced weight gain for schizophrenia patients
Lin, C., Lin, S., Huang, Y., Wang, F., & Huang, C. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.02.058 · Cited by 14
Meola, T. R., Kamath, S., Elz, A. S., Prestidge, C. A., Wignall, A., & Joyce, P. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114453 · Cited by 10
Andrei, C., Zanfirescu, A., Ormeneanu, V.-P., & Negreș, S. (2025) · Antibiotics · doi:10.3390/antibiotics14020138 · Cited by 13
Maślińska, M., Trędzbor, B., & Krzystanek, M. (2021) · Reumatologia/Rheumatology · doi:10.5114/reum.2021.107588 · Cited by 9
“Previous attempts to administer probiotics to schizophrenia patients have not resulted in any significant changes in their symptoms [51, 52].”
BackgroundDisrupted diurnal oscillations of the gut microbiota in patients with alcohol dependence
Zhao, K., Ni, Z., Qin, Y., Zhu, R., Yu, Z., Ma, Y., Chen, W., Sun, Q., Wang, Z., Liu, Y., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1127011 · Cited by 10
Janowska, M., Róg, J., & Karakuła‐Juchnowicz, H. (2021) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/132452 · Cited by 6
Chen, H., Cao, T., Lin, C., Jiao, S., He, Y., Zhu, Z., Guo, Q., Wu, R., Cai, H., & Zhang, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1550015 · Cited by 7
Small Bowel—Key Player in Health and Disease
Marlicz, W. M., & Koulaouzidis, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101748 · Cited by 4
“Future investigations [23] into the pathophysiology of host-microbe interactions should focus on the small bowel [24,25], which is still relatively inaccessible.”
BackgroundPsycho-pharmacomicrobiomics: a systematic review and meta-analysisPreprint
Minichino, A., Person, T., Fanshawe, J. B., Fusar‐Poli, P., McGuire, P. K., Burnet, P. W. J., & Lennox, B. (2023) · Research Square · doi:10.21203/rs.3.rs-2780131/v1 · Cited by 4
Villagomez, P. E., Hinojosa-Figueroa, M. S., Vallejo, P., Pérez, F., Burneo, G., Villarreal, C., Rodas, J. A., & León-Rojas, J. E. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1728473 · Cited by 10
Tufvesson‐Alm, M., Walsh, L., Pierce, S., Keohane, F., Clarke, G. A., O’Connor, K. M., Cryan, J. F., & Schellekens, H. (2026) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2026.2637716 · Cited by 5
“Here, only one observational study considered sex differences and reported that weight gain was only observed in females following six weeks of olanzapine (OlZ) treatment (Pełka-wysiecka et al. 2019).”
Dhieb, D., & Bastaki, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1778794 · Cited by 2
“…studies show robust compositional changes: in one cohort of acutely ill, hospitalized patients treated with olanzapine, significant weight gain occurred without major shifts in overall microbiota composition, highlighting the influence of factors such as diet, duration, and host background (83).”
Linking the relationship between drug-induced osteoporosis and the gut microbiota
Martiniaková, M., Šarocká, A., Pénzes, N., Mondočková, V., Ševčíková, A., Čierniková, S., Kováčová, V., Bíro, R., Folwarczna, J., & Omelka, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1818207 · Cited by 2
“Although clinical improvements and increases in BMI were noted in patients with schizophrenia treated with olanzapine, no changes in GM composition were observed (181).”
Marin, S., Jian, C., Ávila-Aguirre, A., Raventós, H., & Salonen, A. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100081 · Cited by 2
Natural molecules in the treatment of schizophrenia
Munawar, N., Ahsan, K., & Ahmad, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00011-7 · Cited by 2
Clinical Translation of Microbe-Based Therapies
Murthy, S., Balagurunathan, R., Anbalmani, S., & Nagarajan, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-1777-4_11 · Cited by 1
Microbiome and bipolar disorder
Salagre, E., Moreno, J. A., & Grande, I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821398-8.00004-7
Gut Microbiota-Mediated Modulation of Neurodevelopmental Behavior in CLCN4- Deficient MicePreprint
Choi, Y., Bose, S., Oh, J., Song, E., Nam, Y., Jeon, S., & Kim, H. (2025) · Research Square · doi:10.21203/rs.3.rs-7514097/v1
Yuan, H. S., Wang, M.-Y., Liu, R., Sreekissoon, S., Liu, Q., Tan, L., Zhao, Y., Zhong, M., Zhang, Q., Su, X.-L., et al. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1673931 · Cited by 1
Papacocea, R.-I., Gabriela, M. A., Radu-Ștefan, V., Russomano, T., & Papacocea, I. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198471
“In a prospective olanzapine-treated cohort, baseline community structure and metabolic potential varied between individuals despite relatively modest average taxonomic changes during follow-up [21].”
Metadata
- Authors
- Pełka-Wysiecka, J., Kaczmarczyk, M., Bąba-Kubiś, A., Liśkiewicz, P., Wroński, M., Skonieczna-Żydecka, K., Marlicz, W., Misiak, B., Starzyńska, T., Kucharska-Mazur, J., Łoniewski, I., & Samochowiec, J.
- Affiliations
- Pomeranian Medical University (PL)
- Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Broniewskiego 24, 71-460 Szczecin, Poland
- Wroclaw Medical University (PL)
- Department of Gastroenterology, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, Poland
- Department of Psychiatry, Pomeranian Medical University in Szczecin, Broniewskiego 26, 71-460 Szczecin, Poland
- Corresponding author
- Łoniewski, Igor
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-10-03
- Volume
- 8
- Issue
- 10
- Pages
- 1605
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC6832832
- OpenAlex
- W2977720542
- Cited by
- 59
- References
- 74
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 10 · 2019: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Narodowym Centrum Nauki (UMO-2018/31/B/NZ5/00527)
- Fundusz Stymulacji Nauki (FSN-312-05/15)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, schizophrenia, olanzapine, atypical antipsychotics, fecal microbiota composition, body mass index, weight gain, Prevotella, Bacteroides, Blautia, Clostridium, symptom severity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.